Drugs / tumor-derived donor lymphocyte
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01445132 | Jan 2007 → Apr 2013 | B-cell chronic lymphocytic leukemia | National Cancer Institute (NCI) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | tumor-derived donor lymphocyte | “We tested the feasibility and safety of costimulated, tumor-derived donor lymphocyte (TDL) infusion in a phase 1 trial.” PMID 22289893 ↗ Jan 2012 |
| Known as | TDL | “We tested the feasibility and safety of costimulated, tumor-derived donor lymphocyte (TDL) infusion in a phase 1 trial.” PMID 22289893 ↗ Jan 2012 |
| Modality | Cell therapy | “TDL are a feasible, tolerable, and novel donor cell therapy alternative for relapse after AlloSCT.” PMID 22289893 ↗ Jan 2012 |